Incyte doubles down on CEO Hervé Hoppenot’s pay package — big but not stupid
On Monday, as Incyte’s stock price $INCY headed south in the wake of the FDA’s surprising decision to boot back baricitinib, the biotech was outlining how it nearly doubled CEO Hervé Hoppenot’s compensation package in 2016.
In the proxy statement, Incyte noted a small bump in base pay, to $937,738. But it was the increase in stock and option awards where the CEO benefited the most. Combined, the awards jumped from $3.7 million in 2015 to $9.5 million last year. And his total package grew from just under $6 million to $11.8 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
